CD56+ blastic transformation of chronic myeloid leukemia involving the skin

Journal of Cutaneous Pathology

Volumn 26, Issue 10, 1999, Pages 497-503

  Kaddu, Steven ^a   Beham Schmid, Christine ^a   Zenahlik, Paul ^a   Kerl, Helmut ^a   Cerroni, Lorenzo ^a  

^a UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CD15 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CD68 ANTIGEN; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; LEUKOSIALIN; NERVE CELL ADHESION MOLECULE; PARAFFIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST TRANSFORMATION; BONE MARROW; CANCER INVASION; CASE REPORT; CHRONIC MYELOID LEUKEMIA; HUMAN; IMMUNOHISTOLOGY; MALE; PAPULE; SKIN; SKIN DEFECT; STEM CELL; TUMOR CELL;

EID: 0032732809     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0560.1999.tb01796.x     Document Type: Article

References (40)

1. Muehleck SD, McKenna RD, Arthur DC, Parkin JL, Brunning RD. Transformation of chronic myelogenous leukemia: Clinical, morphologic and cytogenic features. Am J Clin Pathol 1984; 82: 1.
2. Rosenthal S, Canellos GP, De Vita VT, Gralnick HR. Characteristics of blast crisis in chronic granulocytic leukemia. Blood 1977; 49: 705.
3. Ross DW, Brunning RD, Kantarjian HM, et al. A proposed staging system for chronic myeloid leukemia. Cancer 1993; 71: 3788.
4. Velasquez ET, Verma RS, Krishnamurthy M, Dosik H. Extra-medullary presentation of Blast crisis in chronic myelogenous leukemia. Acta Haemat 1985; 74: 52.
5. Ratnam KV, Khor CJ, Su WPD. Leukemia cutis. Dermatol Clin 1994; 12: 419.
6. Cerroni L, Zenahlik P, Hoffer G, Kaddu S, Smole J, Kerl H. Specific cutaneous infiltrates of B-cell chronic lymphocytic leukemia: A clinicopathologic and prognostic study of 42 patients. Am J Surg Pathol 1996; 20: 1000.
7. Murphy WG, Fotheringham GH, Busuttil A, Allan NC. Skin lesions in chronic granulocytic leukemia: Treatment of a patient with topical nitrogen mustard. Cancer 1985; 55: 2630.
8. Buechner SA, Li CY, Su WPD. Leukemia cutis: A histopathologic study of 42 cases. Am J Dermatopathol 1985; 7: 109.
9. Ratnam KV, Su WPD, Ziesmer SC, Li CY. Value of immunohistochemistry in the diagnosis of leukemia cutis: Study of 54 cases using paraffin-section markers. J Cutan Pathol 1992; 19: 193.
10. Morrow GW, Pease GL, Stroebel CF, Bennet WA. Terminal phase of chronic myelogenous leukemia. Cancer 1965; 18: 369.
11. Muss HB, Moloney WC. Chloroma and other myeloblastic tumors. Blood 1973; 42: 721.
12. Kaddu S, Zenahlik P, Beham-Schmid C, Kerl H, Cerroni L. Specific cutaneous infiltrates in patients with myelogenous leukemia: A clinicopathologic study of 26 patients with assessment of diagnostic criteria. J Am Acad Dermatol 1999; 40: 966.
13. Su DWP, Buechner SA, Li CY. Clinicopathologic correlations in leukemia cutis. Am Acad Dermatol 1984; 11: 121.
14. Kaiserling E, Horny HP, Geerts ML, Schmid U. Skin involvement in myelogenous leukemia: Morphologic and immunophenotypic heterogeneity of skin infiltrates. Mod Pathol 1994; 7: 771.
15. Sepp N, Radaszkiewicz T, Meijer CJL, et al. Specific skin manifestations in acute leukemia with monocytic differentiation. Cancer 1993; 71: 124.
16. Bennett JM, Catovsky D, Daniel MT, et al. The chronic myeloid leukemias: Guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myclomonocytic leukemia: Proposals by the French-American-British Cooperative Leukemia Group. Br J Haematol 1994; 87: 746.
17. Kurzrock R, Talpaz M. The molecular pathology of chronic myelogenous leukemia. Br J Haematol 1991; 79: 34.
18. Kurzrock R, Kantarjian HM, Shtalrid M, Gutterman JU, Talpaz M. Philadelphia chromosome-negative chronic myclogenous leukemia without breakpoint cluster region rearrangement: A chronic myeloid leukemia with a distinct clinical course. Blood 1990; 75: 445.
19. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189.
20. Cunningham BA, Hemperly JJ, Murray BA, Prediger EA, Brackenbury R, Edelman GM. Neural cell adhesion molecule: Structure, immunoglobulin-like domains, cell surface modulation and alternative RNA splicing. Science 1987; 236: 799.
21. Williams AF, Barclay AN. The immunoglobulin superfamily: Domains for cell surface recognition. Annu Rev Immunol 1988; 6: 381.
22. Wong KF, Chan JK, Ng CS, et al. CD56 (NKH1)-positive hematolymphoid malignancies. Hum Pathol 1992; 23: 798.
23. Wong KF, Chan JK, Ng CS. CD56(NCAM)-positive malignant lymphoma. Leuk-Lymphoma 1994; 14: 29.
24. Jaffe ES, Chan JK, Su IJ, et al. Report of the workshop on nasal and related extranodal angiocentric T-natural killer cell lymphomas: Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996; 20: 103.
25. DiGiuseppe JA, Louie DC, Williams JE, et al. Blastic natural cell leukemia/lymphoma: A clinical study. Am J Surg Pathol 1997; 21: 1223.
26. Scott A, Head DR, Kopecky KJ, et al. HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell leukemia acute potentially misdiagnosed as French-American-British acute myeloid leukemia-M3. Blood 1994; 84: 244.
27. Byrd JC, Weiss RB. Recurrent granulocytic sarcoma: An unusual variation of acute myelogenous leukemia associated with 8;21 chromosomal translocation and blast expression of neural cell adhesion molecule. Cancer 1994; 73: 2107.
28. Krishnan, K, Ross CW, Adams PT, Pereira A, Roth MS. Neural cell-adhesion molecule (CD56)-positive, t(8;21) acute myeloid leukemia (AML, M-2) and granulocytlc sarcoma. Ann Hematol 1994; 69: 321.
29. Baer MR, Stewart CC, Lawrence D, et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21) (q22;q22). Blood 1997; 90: 1643.
30. Iizyka Y, Aiso M, Oshimi K, et al. Myeloblastoma formation in acute myeloid leukemia. Leuk Res 1992; 16: 665.
31. Lanza F, Bi S, Castoldi G, Goldman JM. Abnormal expression of N-CAM(CD56) adhesion molecule on myeloid and progenitor cells from chronic myeloid leukemia. Leukemia 1993; 7: 1570.
32. Mann KP, DeCastro CM, Liu J, et al. Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes. Am J Clin Pathol 1997; 107: 653.
33. Suzuki R, Yamamoto K, Seto M, et al. CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia: A distinct hematolymphoid disease entity. Blood 1997; 90: 2417.
34. Seymour JF, Pierce SA, Kantarjian HM, Keating MJ, Estey EH. Investigation of karyotypic, morphologic, and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). Leukemia 1994; 8: 823.
35. Ansell JE, Bhawan J, Pechet L. Leukemia cutis in blastic transformation of chronic myelocytic leukemia: TdT positive blasts and response to vincristine and prednisone. J Cutan Pathol 1980; 7: 302.
36. Tsurumi H, Takahashi T, Koshino Y, et al. [Acute megakaryoblastic leukemia with leukemia cutis, meningeal leukemia, and myelofibrosis (in Japanese). Rinsho Ketsueki 1991; 32: 1475.
37. Chan AC, Kwong YL, Lam CC. Granulocytic sarcoma or megakaryoblastic differentiation complicating chronic idiopathic myelofibrosis. Hum Pathol 1996; 27: 417.
38. Bettelheim P, Lutz D, Madjic O, et al. Cell lineage heterogeneity in blast crises of chronic myeloid leukemia. Br J Haematol 1985; 59: 395.
39. Hernandez JM, González-Sarmiento JM, Martin C, et al. Immunophenotypic, genomic and clinical characteristics of blast crisis or chronic myelogenous leukemia. Br J Haemotol 1991; 79: 408.
40. Nair C, Chopra H, Shinde S, et al. Immunophenotype and ultrastructural studies in blast crisis of chronic myeloid leukemia. Leuk-Lymphoma 1995; 19: 309.